Justin Hanka’s Post

Efficacy of Cariprazine in Preventing Relapse in Bipolar I Disorder: A Phase 3b Study Study 👇 After an open label period of treatment and remission 👇 Patients were randomized to receive Cariprazine at 1.5 mg/day, 3.0 mg/day, or placebo for up to 39 weeks in the double-blind period. Relapse Rates: 👉17.9% for 3.0 mg/day 👉16.8% for 1.5 mg/day 👉19.7% for the placebo group. Efficacy of Treatment: ❌👉No significant difference in preventing relapses was found between either cariprazine dose and placebo. Adverse Events: 🚨 👉Most common were akathisia, headache, insomnia, and nausea during the open-label period; increased weight and insomnia were noted in the double-blind period. “Cariprazine was not superior to placebo in the prevention of relapses in this study. Relapse rates were unusually low in the placebo group. Cariprazine was well-tolerated”. Paper👉 McIntyre RS, Davis B, Rodgers J, Rekeda L, Adams J, Yatham LN. Cariprazine as a maintenance therapy in the prevention of mood episodes in adults with bipolar I disorder. Bipolar Disord. 2024 #cariprazine #bipolardisorder

🧠💡 Ahead of a crucial FDA meeting, discussions are swirling around Lykos Therapeutics' innovative ecstasy-based PTSD treatment. Big question - does the breakthrough outweigh the risks? 🤔 After extensive trials where symptoms plunged with MDMA, we're on the brink of a new era for mental health. But the FDA probes deeper, flagging issues of 'functional unblinding' and incomplete data on long-term health impacts. 🧐 Will these concerns overshadow the therapy's potential to revolutionize PTSD care? What's certain is the road to approval is as complex as the condition itself. 🚦 #PTSDTreatment #MentalHealthInnovation #EthicalPharmacology

one of the first clincial trials for use of #mdma to assess efficacy for post-traumatic stress disorder begins soon in NSW in #australia. The Therapeutic Goods Administration approved MDMA for controlled use when prescribed by a psychiatrist for people with PTSD. This made Australia the first country to recognise #psychedelics as medicines. There is growing evidence to suggest MDMA can reduce fear and anxiety for people with {TSD when coupled with pain therapy, however professional bodies continue to urge caution. in April this year in Europe a €6.5 million study "PsyPal" the first funded clinical research project into psychedelic-assisted mental health treatments commenced. The PsyPal research team is aiming to start dosing patients in January 2025, with the trial running for two years. Companies such as atai Life Sciences are at forefront of increasing awareness of potential therapeutic benefits of Psilocybin and MDMA. more at: https://lnkd.in/e-Yk3U2k Emyria (ASX:EMD) Michael Winlo Florian Brand

Do you suffer from Depression? tVNS® led to a reduction of depression-specific HAMD score of minimum 2-3 points in adult patients when used in parallel with psychopharmacological and psychotherapy treatments after a period of 9 weeks. Thousands of patients have put their trust in tVNS® and have found great results in managing their neurological conditions. With its non-invasive approach, patient-centered therapies, and minimal adverse effects, tVNS® presents a fresh perspective of hope and comfort for individuals who are struggling to manage their Depression. If you are currently struggling with Depression or know someone who is, please explore our website for more details & success stories on how our tVNS® device can help manage symptoms of Depression. tVNS® is certified as a Class lla medical device under the European Medical Device Regulation (MDR), and offers trusted and safe therapy for managing neurological, mental and physical health conditions. #depression #depressionsymptoms #livingwithdepression #depressionsymptoms #tvns

The Phase 1 results of BPL-003 (intranasal 5-MeO-DMT) have been published in the well-regarded and peer-reviewed Journal of Psychopharmacology. Our Co-Founder and CEO, Florian Brand commented: “Consistent with the initial Phase 2a results reported recently, the Phase 1 results showed that BPL-003 was safe and well-tolerated and underscores its potential as a scalable interventional treatment requiring two hours or less in the clinic, in line with the treatment paradigm successfully established by Spravato.” BPL-003 is currently being investigated by Beckley Psytech in Phase 2a studies as a potential treatment for Alcohol Use Disorder (AUD) and Treatment Resistant Depression (TRD). Additionally, it’s being explored in a Phase 2b study for TRD, with initial results expected in H2 2024. Press release here: https://lnkd.in/eVfwD2Ug  Publication here: https://lnkd.in/eGQksdYJ #journal #publication #mentalhealth #depression

Elevate your understanding of psychopharmacology and unlock new avenues for effective patient care by joining us for a complimentary webinar this Friday, September 27th. 🗓️ This presentation will provide a general overview of psychopharmacologic interventions for mood and anxiety disorders while reviewing basic pharmacology of mood and anxiety medications. We'll also discuss the role of psychotherapists within the multidisciplinary team, highlighting the importance of collaboration with psychiatrists in treating these disorders. By attending this event, you'll learn how to: - Describe the potential benefit of referring patients with mood and anxiety disorders for psychopharmacologic treatment and collaborating with physicians and other prescribers with shared treatment goals. - Identify medical illnesses that can look like mental health issues and medications that can exacerbate or cause mental health symptoms - Discuss the most common risks and benefits for the most common medications used in the management of Depression, Anxiety, Bipolar Disorder and Schizophrenia Register here 🔗 : https://bit.ly/3MSmMrr

Click on the following link to read the article: Clinical insights for major depressive disorder https://hubs.la/Q02G1p650. This overview of MDD includes clinical presentation, pathophysiology, diagnosis and treatment: 1. Case Vignette: Illustrates common challenges in MDD management, like medication timelines and therapy adjustments 2. Detailed Pharmacotherapy Discussion: SSRIs, SNRIs and other antidepressant classes plus adjunctive therapies like CBT 3. Guidance for Improved Treatment Outcomes: The importance of a multidisciplinary approach and regular monitoring 4. Recognising the Risks: Ongoing management and preventive strategies Mark Mental Illness Awareness Month this July by understanding more about MDD – a chronic, recurrent condition with significant morbidity.

New Study Reveals the Long-Term Cognitive and Psychiatric Impact of COVID-19 COVID-19 has left a lasting mark on our world, but a new study from the University of Oxford reveals just how deep that mark goes. The research highlights significant long-term cognitive and psychiatric effects in those who’ve had the virus, even in mild cases. Memory lapses, brain fog, anxiety, and depression—these are just some of the challenges people are facing months, even years after infection. The study serves as a stark reminder that the pandemic's impact isn't just physical; it's mental too. The implications are profound. We need to rethink how we support those recovering from COVID-19, not just in the short term but in the long run. The focus now must shift to understanding and addressing these long-term effects to truly heal as a society. At The Real Gut Doctor, we offer a post-viral infection regenerative protocol designed to address the concerns, struggles, and issues of Long COVID. If you're experiencing these lingering effects, let us help you reclaim your health. Call today for a free discovery call. #COVID19 #MentalHealth #BrainFog #LongCOVID #CognitiveHealth #PsychiatricImpact #HealthResearch #PandemicEffects #OxfordStudy #PublicHealth #RegenerativeMedicine

PANS/PANDAS exists - it’s not up for debate. 👉 The conditions are characterized by a sudden onset of OCD and/or tics, accompanied by other psychiatric symptoms such as anxiety, mood swings, and aggression. They’re believed to be triggered by infections, leading to an autoimmune response that affects the brain. We need to keep learning more about them and spreading awareness because swift diagnosis can lead to more effective interventions. And when it comes to neurological disorders, waiting around is not recommended. Your brain is incredibly important! 🙏 At TicTock Therapy, we're committed to boosting awareness and providing tailored treatments that offer hope and healing to children and their families. For more resources, visit the Children's e-Hospital. Get in touch. #MentalHealth #Therapy #PANDAS

Well-minded psychopharmacology is a vital component when treating personality disorders. Watch the full lecture, presented by Dr. Thomas Schwartz, to learn what treatments work and which may not be effective in patients with borderline personality disorders. NEI Members can watch the full lecture here https://nei.global/encore Presented at the 2023 NEI Congress session titled, "Nothing Personal: Diagnosis and Treatment of Personality Disorders".